Abstract Library

#4668 Predictive factors of postoperative recurrence in patients with neuroendocrine tumour of the lung: Prospective analysis of clinicopathologic features and radiomics

Introduction: In localised and locally advanced forms neuroendocrine tumours (NETs) of the lung radical surgical resection represents the standard of care, several clinicopathologic factors are potentially associated with recurrence of disease.

Conference:

Presenting Author: Paravani P

Authors: Paravani P, Russo F, Mazzilli R, Zamponi V, Mancini C,

Keywords: radiomics, predictive role, rfs, lung, lung net,

#4515 Prognostic factors for survival in patients with metastatic small intestinal neuroendocrine tumours undergoing primary tumour resection

Introduction: Although guidelines recommend primary tumour resection in metastatic small intestinal neuroendocrine tumours (SI-NETs) to manage symptoms and complications, the survival benefit and optimal surgical approach remain unclear.

Conference:

Presenting Author:

Authors: Dell' Unto E, Ogunbiyi O, Mirnezami R, Malam Y, Yasin Y,

Keywords: Small Intestinal Neuroendocrine Tumour, surgery, midgut carcinoid,

#4091 Grade 2 (G2) gastro-entero-pancreatic (GEP) neuroendocrine tumors (NETs): Risk stratification beyond Ki-67?

Introduction: G2 GEP-NETs are well-differentiated neuroendocrine neoplasms with Ki-67 proliferation index of 3-20%. Rather than behaving as a monolithic category, these neoplasms are often characterized by an unpredictable outcome, and additional biomarkers are needed.

Conference:

Presenting Author:

Authors: Laffi A, Zerbi A, Lavezzi E, Carrara S, Rossi E,

Keywords: GEP NET, G2, neuroendocrine tumor, neuroendocrine,

#4054 Predictive factors of persistent thrombocytopenia after 177Lu-DOTATATE in patients with neuroendocrine tumors

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) is an effective and well tolerated treatment for advanced Neuroendocrine Tumors (NET). However, some Persistent Thrombocytopenia (PT) are described and may compromise further therapies and outcome.

Conference:

Presenting Author:

Authors: Oziel-Taieb S, Ferrara R, Charrier N, Maniry J, Reichert T,

Keywords: Neuroendocrine Tumor, PRRT, LuDOTATATE, Thrombocytopenia, Bone metastases, spleen,

#3980 Interest of serum and urinary 5HIAA, serotonin, chromogranin A and NT-proBNP assays as predictive factors for the development of carcinoid heart disease in neuroendocrine tumors

Introduction: Carcinoid heart disease (CHD) is the main complication of carcinoid syndrome (CS) in patients with neuroendocrine tumors (NETs) and has a poor prognosis, with treatment based mainly on high-risk valve replacement surgery.

Conference:

Presenting Author: Walter T

Authors: Lecoeur A, Sfeir R, Damour J, Lombard-Bohas C, Gerard L,

Keywords: neuroendocrine tumors, carcinoid syndrome, carcinoid heart disease, serum 5HIAA, urinary 5HIAA, serotonin, chromogranin A, NT-proBNP,